Long-term data suggests Baxter's Gammagard stabilises Alzheimer's symptoms
This article was originally published in Scrip
New research suggests that continued use of Baxter's intravenous immunoglobulin (IVIG) product, Gammagard, could help stabilise the symptoms of Alzheimer's disease. Patients in the three-year Phase II extension study were said to suffer no decline in cognition, memory, daily functioning and mood.
Register for our free email digests: